Background Although statin-related myopathy is a common adverse event, diagnostic criteria and standard treatments have not yet been established. Furthermore, statin-related myopathy is a major concern because of intolerance and discontinuation of statin agents.
Introduction
Hyperlipidemia is a risk factor of atherosclerosis, cardiovascular disease, and cerebrovascular disease. To prevent the development of these conditions, it is crucial to control hyperlipidemia according to the severity of underlying disease. The MEGA study demonstrated that statin agents control hyperlipidemia and suppress cardiovascular events and cerebrovascular diseases 1) . Consequently, statin agents play a major role in the control of atherosclerosis-related diseases.
The adverse effects of statin agents include hepatic dysfunction, renal dysfunction, statin-related myopathy, and rhabdomyolysis. Among these, statin-related myopathy and rhabdomyolysis are major concerns because they result in intolerance and discontinuation of statin agents.
We conducted a retrospective analysis the patients with hyperlipidemia who had been receiving statin agents to compare the risk factors between patients with high creatine kinase (CK) levels and those with normal CK levels.
Patients and methods
Twenty patients with hyperlipidemia were referred to our institution between April 1, 2011 and March 31, 2012 . These 20 patients included 4 men and 16 women whose ages ranged from 57 to 92 years (mean age: 75 years). We retrospectively analyzed the value of CK, statin-related myopathy, and the risk factors of statin-related myopathy in these 20 patients with hyperlipidemia. We excluded ischemic heart disease by electrocardiogram, echocardiogram, and measurement of cardiac enzymes. This retrospective study was conducted in compliance with good clinical practices and the ethical principles of the Declaration of Helsinki. This study was approved by the Review Committee of Cooperative and Commissioned Research and the Ethics Committee of the University of Miyazaki Faculty of Medicine (No. 1047). more, 2 (case 1 and 2) of these 5 patients developed statin-related myopathy. They included 1 woman and 1 man (57 and 60 years old, respectively). To elucidate the risk factors of statin-related myopathy, we retrospectively studied the clinical manifestation, diagnosis, and treatment of statin-related myopathy in these patients.
Of the 5 patients in the CK-high group ( Table 2) , 2 patients (Case 1 and 2) had muscle symptoms; therefore, we diagnosed statin-related myopathy based on the guidelines of the American College of Cardiology/American Heart Association/National Heart, Lung, and Blood Institute (ACC/AHA/NHLBI) 2, 3) . After four weeks discontinuation of atorvastatin, the patients became symptom-free and CK was normalized immediately in both cases. Subsequently, we administered pitavastatin for 2 cases. The other 3 patients (case 4, 11 and 19) in the CK-high group showed mild CK elevation without muscle symptoms, and so, they continued therapy with the same statin.
(Risk factors for development of statin-related myopathy) In addition, the 20 patients receiving statin treatment were divided into the following 2 groups: a CK-high group (n = 5) and a CK-normal group (n = 15) ( Table 3) . We retrospectively analyzed patient characteristics between the CK-high and CK-nor- BMI, concomitant treatment with certain cytochrome P450 inhibitors, and a decline in renal and hepatic function 7) . According to the analysis of patient characteristics between the CK-high and CK-normal groups, patients who were relatively younger and had hepatic dysfunction showed increased serum CK levels (p < 0.05; Table 3 and Fig. 1) . In the CK-high group, 3 of the 5 patients (60%) had hepatic dysfunction due to fatty Fig. 1 Statistical analysis of patient parameters in the CK-high and CK-normal groups liver and 4 of the 5 patients (80%) were on statins that inhibit cytochrome P450. In addition, 3 of the 5 patients (60%) were administered PPIs that also inhibit cytochrome P450. Below, we summarize the 2 cases (case 1 and 2) of statin-related myopathy.
(Case series developed statin-related myopathy) Case 1 (Fig. 2) : A 57-year-old woman was diagnosed with hyperlipidemia and diabetes mellitus. Initially, she was administered pitavastatin at 1 mg/day. To further control hyperlipidemia in this patient, pitavastatin was changed to atorvastatin at 5 mg/ day. Three months after initiation of atorvastatin treatment, she complained of a lump and tenderness in her right lower leg, and her CK levels were found to be elevated to 377 IU/L. Immediately, atorvastatin was discontinued during four weeks. Subsequently, treatment of this patient was switched back to 1 mg/day pitavastatin. She became symptom-free, and CK was normalized immediately.
Case 2 (Fig. 3) : A 60-year-old man suffered from acute myo-cardial infarction and was diagnosed with hyperlipidemia. He was administered pitavastatin at 1 mg/day. To further control hyperlipidemia in this patient, pitavastatin was changed to atorvastatin at 10 mg/day. Low density lipoprotein (LDL)-cholesterol was thus lowered to 50 -60 mg/dL, but 10 months after initiation of atorvastatin treatment, the patient complained of a lump and tenderness in his left shoulder, and his CK levels were elevated to 314 IU/L. Administration of atorvastatin was stopped during four weeks. After the patient became symptom-free with normalization of CK levels, treatment was subsequently switched to pitavastatin at 1 mg/day. (Summary of two cases): Two cases were treated for hyperlipidemia with pitavastatin. For further control of hyperlipidemia, treatment was changed to atorvastatin. After initiation of atorvastatin treatment, statin-related myopathy developed at 3 months and 10 months in case 1 and 2, respectively. The symptoms of statin-related myopathy in these patients were a lump and tender- ness in the right lower leg and the left shoulder, respectively. Both cases presented elevation of CK to 377 IU/L and 314 IU/L, respectively. When statin-related myopathy was diagnosed in our cases, statin therapy with atorvastatin was stopped immediately. After four weeks discontinuation of the atorvastatin, statin-related myopathy had gradually resolved, and statin-switching therapy was subsequently initiated and maintained for control of hyperlipidemia. We selected pitavastatin, which had been previously administered, for statin-switching therapy. There was no further development of statin-related myopathy after statin-switching therapy was initiated. Both patients were also administered a PPI, which had cytochrome P450 inhibitory properties.
Discussion
Although statin-related myopathy is a common adverse effect of statin agents, the precise mechanisms of this condition remain unclear. The major problems associated with statin-related myopathy are intolerance and discontinuation of statin agents. One of the proposed mechanisms of statin-related myopathy is decreased cholesterol content of skeletal myocyte membranes leading to instability, depletion of isoprenoids or coenzyme Q10, and mitochondrial dysfunction 4, 5) . An observational study has reported that the incidence of statin-related myopathy is approximately 5-10%, and the duration of onset of statin-related myopathy is approximately 6.3 months 6) .
According to the guidelines of the Mayo clinic, before starting statin therapy, measurement of baseline CK levels should be considered in high-risk patients, such as those who are older, who are receiving concomitant medications known to increase myotoxicity, or who have renal or hepatic dysfunction 7) . Patientrelated risk factors for statin-related myotoxicity was reported to be female gender, low BMI, concomitant treatment with certain cytochrome P450 inhibitors, and a decline in renal and hepatic function 7) . Moreover, Marcus FI reviewed that statin-related myopathy were associated with dose related manner, the statin such as simvastatin, and drug-drug interactions 8) . In our retrospective study, our clinical findings strongly indicate that a relatively younger age may also be a risk factor for statin-related myopathy, although the patient number in the current study was small, and all cases were studied in a single institution. The quantity of muscle may be one of the reason for younger age as a risk factor for statin-related myopathy. In case 1, hepatic dysfunction due to fatty liver and hepatitis B infection were thought to contribute to myopathy, and in case 2, severe reduction of LDL cholesterol may have contributed to statin-related myopathy. In addition, both patients were administered a PPI, and therefore were receiving concomitant treatment with a cytochrome P450 inhibitor. Furthermore, among the 20 patients on statin treatment, patients receiving atorvastatin (a cytochrome P450 inhibitor) had a high tendency for the development of CK elevation (3/7 patients).
As regarding to treatment for statin-related myopathy, immediate cessation of statin treatment was important after the diagnosis of statin-related myopathy. Although a standard treatment for statin-related myopathy has not been established, various strate-gies reported include low dose statin therapy, non-daily regimen therapy, switching therapy, and non-statin alternative therapy after recovery from statin-related myopathy 9, 10) . Joy reported that switching therapy, such as a change in treatment to low dose rosuvastatin or fluvastatin, might be one of the treatment options for statin-related myopathy 11) . Leung A reviewed that a useful clinical approach was to provide a 2-week statin holiday for muscle symptons during administration of the statin agent 12) . In our cases, atorvastatin treatment was stopped immediately when statin-related myopathy was diagnosed. Four weeks after the discontinuation of the statin agent, the elevation of CK and statinrelated myopathy was resolved. Subsequent switching to a noncytochrome P450 inhibitor statin may be safer than treatment with a cytochrome P450 inhibitor statin. In Japan, to elucidate the efficacy and safety of strong statin agents, the PATROL trial and the LIVES study were performed and indicated the efficacy of strong statins [13] [14] [15] . In our cases, statin-switching therapy to a previously prescribed non-cytochrome P450 inhibitor statin was safe and effective for statin-related myopathy. There are differences in high dose statin use between countries and genetic determinants of cytochrome P450 metabolism can vary. Therefore, Japanese guidelines for diagnosis and treatment are urgently needed for the appropriate control of statin-related myopathy in the future. In addition, 3 patients (case 4, 11 and 19) in our study showed mild CK elevation without muscle symptoms. However there is no term for muscle symptom-free CK elevation and its risk is unclear in the guidelines of the ACC/AHA/NHLBI 2, 3) (Table 4 ). This clinical condition will be needed to recognized as pre-condition of statin-related myopathy.
This case-oriented study should be helpful to the physicians who directly care for statin-related myopathy patients, and may provide a future direction for performing a more efficient control. 
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Myopathy→a general term referring to any disease of muscles
Myalgia→muscle ache or weakness without CK elevation Myositis→muscle symptoms with increased CK levels Rhabdomyolysis→muscle symptoms with marked CK elevation (typically substantially greater than 10 times the upper limit of normal) and with creatinine elevation(usually with brown urine and urinary myoglobin) * There is no term for symptom-free CK elevation in the guidelines of the ACC/AHA/NHLBI.
